VIP
Vasoactive intestinal peptide. VIP is not FDA approved for any use.
Key facts
- Class
- Vasoactive intestinal peptide
- Also called
- vasoactive intestinal peptide
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- compounded or research
- WADA
- Unclear
- Not named on the 2026 list
VIP guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Heart health | Not in our ledger | Not in our ledger | 3 | Human RCT evidence, 4 of 4Thorax 1986, PMID 3787552 |
| Immune system | Not in our ledger | Not in our ledger | 5 | Human RCT evidence, 4 of 4Medical principles and practice 2025, PMID 39870064 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
Vasoactive intestinal peptide: blood-vessel effects, then lung and erection trials
In 6 healthy subjects given a constant VIP infusion, total peripheral resistance fell by 30% and mean arterial pressure by 12%, with sustained vasodilatation.[14]
In normal subjects, infusion at 6 pmol/kg/min lowered mean systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min.[11]
The best-studied use did not work
In a randomised trial of intravenous aviptadil in COVID-19 hypoxaemic respiratory failure, 90-day deaths were 38% on aviptadil and 36% on placebo (hazard ratio 1.04).[15]
A 60-day randomised trial of intravenous aviptadil in critical COVID-19 respiratory failure missed its primary end point (alive and free from respiratory failure at day 60; OR 1.6, 95% CI 0.86-3.11).[16]
The same abstract reports a statistically significant two-fold odds of improved survival at 60 days (OR 2.0, p = 0.035) alongside the missed primary end point.[16]
A meta-analysis of aviptadil in ARDS found a survival odds ratio of 1.01, indicating no significant benefit.[17]
Other forms and uses are narrow
Aviptadil with phentolamine by injection into the penis was rated effective by 59% of men in a retrospective series; it is a different route and combination.[18]
Inhaled VIP in sarcoidosis was safe and well-tolerated in a small uncontrolled study and reduced TNF-alpha production by lung-fluid cells.[19]
Regulatory path
Drugs@FDA lists no VIP product.[2]
FDA's compounding category list names Vasoactive Intestinal Peptide as a bulk substance.[3]
Common questions
Is VIP FDA approved?
No. VIP is not FDA approved for any use.
What is VIP peptide?
A peptide whose infusion in healthy subjects caused sustained vasodilatation.[14]
What does VIP peptide do?
In normal subjects, an infusion lowered systolic blood pressure and raised heart rate.[11]
Is there a VIP nasal spray?
The cached human studies used inhaled, intravenous or injected VIP; no nasal spray study was found.[19]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "VIP" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3US compounding: Vasoactive intestinal peptide is listed in FDA's 503A category 1 (bulk drug substances under evaluation).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 4Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025PMID 39870064Accessed 2 Oct 2026
- 5PubMed search: aviptadil[tiab] (30 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (1509 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (70 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: "vasoactive intestinal peptide"[tiab] AND (CIRS[tiab] OR "inflammatory response syndrome"[tiab] OR mycotoxin*[tiab] OR "water-damaged"[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: "vasoactive intestinal peptide"[tiab] AND ("clinical trial"[pt] OR randomized[tiab]) AND (inhal*[tiab] OR intranasal[tiab] OR sarcoid*[tiab] OR "pulmonary hypertension"[tiab] OR ARDS[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
- 12PubMed search: aviptadil[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (humans[mh]) (94 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
- 15Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
- 16The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
- 17Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025PMID 41368449Accessed 2 Oct 2026
- 18Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.The journal of sexual medicine · 2025PMID 40192471Accessed 2 Oct 2026
- 19Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.American journal of respiratory and critical care medicine · 2010PMID 20442436Accessed 2 Oct 2026
Found an error? Report a correction.